Strategies to Reverse Endothelial Progenitor Cell Dysfunction in Diabetes by Petrelli, Alessandra et al.
 
Strategies to Reverse Endothelial Progenitor Cell Dysfunction in
Diabetes
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Petrelli, Alessandra, Raffaele Di Fenza, Michele Carvello,
Francesca Gatti, Antonio Secchi, and Paolo Fiorina. 2012.
Strategies to reverse endothelial progenitor cell dysfunction in
diabetes. Experimental Diabetes Research 2012:471823.
Published Version doi:10.1155/2012/471823
Accessed February 19, 2015 10:31:46 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10336974
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAHindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 471823, 9 pages
doi:10.1155/2012/471823
Review Article
Strategies to Reverse Endothelial Progenitor
CellDysfunctioninDiabetes
AlessandraPetrelli,1,2 RaffaeleDi Fenza,2 Michele Carvello,3 Francesca Gatti,1
Antonio Secchi,4 andPaolo Fiorina1,2
1Transplantation Research Center (TRC), Nephrology Division, Children’s Hospital and Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA 02115, USA
2Transplantation Medicine, San Raﬀaele Scientiﬁc Institute, 20132 Milan, Italy
3General Surgery, San Raﬀaele Scientiﬁc Institute, 20132 Milan, Italy
4Transplantation Medicine, Universit` a Vita-Salute San Raﬀaele, 20132 Milan, Italy
Correspondence should be addressed to Paolo Fiorina, paolo.ﬁorina@childrens.harvard.edu
Received 17 November 2011; Accepted 13 December 2011
Academic Editor: Gian Paolo Fadini
Copyright © 2012 Alessandra Petrelli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Bone-marrow-derived cells-mediated postnatal vasculogenesis has been reported as the main responsible for the regulation of
vascular homeostasis in adults. Since their discovery, endothelial progenitor cells have been depicted as mediators of postnatal
vasculogenesisfortheirpeculiarphenotype(partiallystaminalandpartiallyendothelial),theirabilitytodiﬀerentiateinendothelial
cell line and to be incorporated into the vessels wall during ischemia/damage. Diabetes mellitus, a condition characterized by
cardiovascular disease, nephropathy, and micro- and macroangiopathy, showed a dysfunction of endothelial progenitor cells.
Herein, we review the mechanisms involved in diabetes-related dysfunction of endothelial progenitor cells, highlighting how
hyperglycemia aﬀectsthediﬀerentstepsofendothelialprogenitorcellslifetime(i.e.,bonemarrowmobilization,traﬃckingintothe
bloodstream,diﬀerentiationinendothelialcells,andhomingindamagedtissues/organs).Finally,wereviewpreclinicalandclinical
strategies that aim to revert diabetes-induced dysfunction of endothelial progenitor cells as a means of ﬁnding new strategies to
prevent diabetic complications.
1.Introduction
Endothelial progenitor cells (EPCs) are a subset of bone-
marrow-derived cells committed to the maintenance
and preservation of vascular turnover, remodeling, and
homeostasis [1]. EPCs are immature cells, endowed with
the capacity to be mobilized from the bone marrow into the
bloodstream in response to growth factors and cytokines
release [2, 3]. EPCs may diﬀerentiate into endothelial cells
and ﬁnally take part in the vascular repair [2, 3]. Since 1997,
when Asahara et al. published on Science the discovery of a
population of circulating CD34+ cells showing proliferative
capacity and ability to diﬀerentiate into mature endothelial
cells in vivo and in vitro [4], much debate on EPCs origin
and controversies on the appropriate isolation method was
generated and several acronyms have been used to refer to
this cell population. Diﬀerent markers have been used to
describe inv i v ocirculating EPCs, among them we should
mention CD34+VEGFR2+, CD34+CD133+VEGFR2+,
CD133+VEGFR2+, and CD133+VeCadherin+ [5]. Several in
vitro c u l t u r em e t h o d st oi s o l a t eE P C sh a v eb e e nr e p o r t e d
as well: colony-forming unit-endothelial cells (CFU-ECs),
circulating angiogenic cells (CACs), and endothelial colony
forming cells (ECFCs) [6]. Early EPCs exhibit a spindle-
shapedmorphology invitro, havepoor proliferativecapacity,
and produce to high extent angiogenic cytokines (e.g.;
VEGF), while late EPCs show a cobblestone morphology in
vitro, highly proliferative activity, and the ability to directly
incorporate into capillary vessels [6]. However, despite
the several subtypes of EPCs, there is agreement in the
literature that EPCs from healthy subjects are able to repair
blood vessels wall and that dysfunctional EPCs are defective2 Experimental Diabetes Research
in angiogenic properties, thus contributing to vascular
diseases and progression of cardiovascular syndrome [7].
Thus, healthy EPCs might represent a precondition for a
functioning cardiovascular system. Indeed, EPCs number
a n df u n c t i o nh a v eb e e nr e p o r t e dt ob ei m p a i r e di nt y p e1
(T1D) and type 2 (T2D) diabetes [8, 9]a sw e l la si np r e s e n c e
of cardiovascular risk factors [10–12], while a normalization
of EPC function was found in euglycemic islet-transplanted
patients [13], despite immunosuppressive treatment, thus
justifying the improvement of diabetic complications in
these patients. We will review how diabetes interferes
with EPC function and subsequently summarize potential
strategies to restore/repair EPC function in diabetic patients.
2.EPCDysfunctioninDiabetes
Diabetes and hyperglycemia may aﬀect EPC function at each
step of their lifetime. In this section we provide evidence of
the current knowledge on diabetes-induced damage during
EPC lifespan.
2.1. Mobilization from Bone Marrow. Several studies have
focused on diabetes-mediated impaired EPC recruitment
in the peripheral blood. Hyperglycemia was shown to
aﬀect bone-marrow-harbored EPCs by generating a diﬀused
endothelial damage, microvascular remodeling, and reduc-
tion in c-kit+ Sca-1+ cells [14] in chemically induced (STZ)
diabetic mice. Moreover, in this model, EPC deﬁciency was
associated with an increased oxidative stress, DNA damage,
and cell apoptosis [14]. The molecules involved in EPC
mobilization process from bone marrow are circulating
molecules like SDF-1α [15, 16], VEGF [17], GM-CSF
[18], IL-8 [19], and cleaving enzymes [2]. SDF-1, which
interacts with CXCR-4 receptor on target cells, is released
by ischemic tissues [15]( v i aaH I F - 1 α-mediated induction)
and is involved in EPC mobilization [15], homing into
vascular structures [15], and diﬀerentiation [16]. Similarly,
the role of VEGF in EPC mobilization has been widely
studied in both humans and mice showing that, following
acute ischemic injury, plasma levels of VEGF increase
rapidly leading to a 50-fold increase in EPC percentage in
the peripheral blood [17]. Among the several mechanisms
involved in the impaired bone marrow mobilization of
EPCs in diabetes, endothelial nitric oxide synthase (eNOS)
dysfunction has been clearly demonstrated [20, 21]. Since
uncoupling of eNOS leads to superoxide anion formation
instead of nitric oxide (NO), Thum et al. hypothesized
that such an altered enzyme activity could have a role in
the reduction of EPC number in diabetic patients because
of hyperglycemia-mediated increased oxidative stress [20].
Moreover, in streptozotocin-induced diabetic rats, EPCs
were 39% less than in controls and this was associated with
eNOS uncoupling in the bone marrow [20]. In a model of
hind-limb ischemia-reperfusion (I/R) injury, plasma levels
of VEGF and SDF-1α were measured and EPCs mobilization
after ischemic injury was studied in diabetic rats and
compared to euglycemic rats [22]. In this study, diabetic rats
proved to be unable to mobilize EPCs after ischemic injury
and this evidence was associated with a reduced release of
VEGF and SDF-1α from ischemic muscle [22]. Interestingly,
Gallagher et al. conﬁrmed the relationship between SDF-1α
reduced production and impaired EPCs peripheral counts
in a diabetic murine model of wound healing [21]. Beyond
soluble molecules, cleaving enzymes have shown a relevant
role in EPCs mobilization: cathepsins (in particular Cathep-
sin L was shown to be essential for autoimmune diabetes in
mice [23]) and elastases are released by neutrophils under
conditioning with G-CSF and promote the cleavage of bonds
between cells and stroma and the cleavage of SDF-1α/CXCR-
4 interaction, thus inducing EPCs shedding; ﬁnally, MMP-9,
aproteolyticenzymefoundtobeactivatedindiabetes[24],is
essential for VEGF and SDF-1α-mediated EPCs mobilization
[2]; indeed eNOS knockout mice (which mediates VEGF
and SDF-1α signaling) promotes a reduced MMP-9 activity
and an impaired MMP-9-mediated progenitor cells release
[25, 26].
2.2. Traﬃcking. Once EPCs have been mobilized in the
bloodstream,theymigratetothesitesofischemia/damage,in
a process known to be mediated by SDF-1α [15] and VEGF
[27]. Segal et al. demonstrated that EPCs harvested from
patients aﬀected by T1D and T2D in presence of SDF-1α
showed an impaired migration compared to healthy control
subjects [28]. The isolated EPCs were also characterized
by a reduced cytoskeleton plasticity [28]. Interestingly, they
demonstrated that treatment with exogenous NO corrects
both migration defect and deformability impairment of dia-
betic EPCs [28]. Moreover, glucose-dependent and protein
kinase C- (PKC-) mediated eNOS uncoupling, which results
in hyperproduction of ROS rather than NO production, is
associated with defective migratory capacity of EPCs from
diabetic patients compared to nondiabetic controls [20].
Leicht et al. observed that late EPCs isolated from patients
with T2D had impaired proliferation and migratory capacity
compared to cells isolated from young healthy donors or
non-diabetic age-matched subjects [29]. Advanced glycation
end-products (AGEs) are known to accumulate in diabetes
and were proven to impair migration and enhance apoptosis
in EPCs cultured from human umbilical cord blood [30].
These eﬀects were inhibited by anti-RAGE antibodies [30].
ThesedatawereconﬁrmedbySunetal.thatchallengedEPCs
with AGE-human serum albumin at diﬀerent concentrations
and found that it signiﬁcantly decreased EPCs migration
[31]. Another way in which diabetes may alter EPCs’
traﬃcking is lipotoxicity. It is known that oxidized LDL
(Ox-LDL) is associated with reduced number and increased
senescenceofEPCsandtheseeﬀectsseemtoberelatedtoAkt
activation, p21 expression, and p53 accumulation [32].
2.3. Survival. EPC traﬃcking in the bloodstream are more
susceptible to diabetes-induced apoptosis. Indeed, a lower
EPCsperipheralcounthasbeendescribedindiabeticmurine
models [21, 33]. Nevertheless, several studies have associated
diabetes with reduced EPCs number when cultured ex vivo,
duetobothanincreasedapoptosis[30,31,34]ordiminished
proliferation [29, 32, 35, 36]. In our study, the percentageExperimental Diabetes Research 3
of circulating EPCs did not diﬀer between T1D patients,
islet-transplanted insulin-independent patients, and healthy
controls, and no signiﬁcant diﬀerences in apoptosis could be
found among these subjects [13]. However, in vitro studies
showedreducednumberandincreasedapoptosisofdiabetic-
derived EPCs while a normalization of both parameters
was evident in islet-transplanted patients. Lower secreting
levels of IL-8 from EPCs cultured from T1D patients and
a dose-dependent decrease of control EPCs number in
presence of IL-8 antagonist (anti-IL-8) induced to speculate
on the role of this chemokine in angiogenesis [13]. Several
other investigators reported a reduced survival of EPCs
cultured ex vivo in hyperglycemic conditions. Chen et al.
cultured diﬀerent subtypes (early and late) of EPCs with
high glucose demonstrating a dose-dependent reduction of
early EPCs number, reduced proliferation, and impaired
migration ability of late EPCs compared to mannitol
treatment [36]. High-glucose-mediated negative eﬀects were
restored by NO treatment and worsened by PI3K or eNOS
inhibition [36]. Interestingly, it has been recently shown that
treatment with adiponectin of human and murine EPCs
prevents accumulation of high-glucose-induced premature
senescence [33]. Other intracellular pathways have been
demonstrated to be involved in EPCs survival in diabetes.
Thep38 MAPK pathwayis activatedin EPCs exposed to high
glucose, inducing a dose-dependent reduction of ex vivo cell
counts [35]. Finally, renin-angiotensin-aldosterone system
has been described to be involved in EPCs survival process.
Indeed, angiotensin II was shown to induce EPCs senescence
[37] and aldosterone to downregulate VEGFR-2 expression
leading to reduced EPCs number ex vivo [38]. These ﬁndings
acquire interest considering that diabetes correlates with
signiﬁcantly higher circulating levels of angiotensin II and
aldosterone [39] and that ACE inhibitors are available in
clinical practice.
2.4. Homing and Diﬀerentiation. Investigators have outlined
several crucial pathways involved in EPCs homing and
diﬀerentiation. Interaction between SDF-1α and CXCR-4 is
again fundamental, given that blockade of either the ligand
or the receptor prevents recruitment to injured sites [15].
In 2007, Gallagher et al. demonstrated that the mechanism
involved in diabetes-mediated EPCs dysfunctional homing
is a reduced local release of SDF-1α and NO in the sites
of wound and that SDF-1α exogenous administration could
lead to a faster recovery of the wound [21]. Impaired
capacity of EPCs to support endothelial tube formation
was evidenced in T1D patients as well [8]. Marchetti et
al. determined the eﬀects of glucotoxicity on EPCs in de
novo tube formation by culturing isolated EPCs from healthy
donors with high glucose or high glucose plus benfotiamine,
a scavenger of glucotoxicity [40]. While glucotoxicity led to
impaired EPCs-mediated tube formation on matrigel (asso-
ciated with a reduced activity of FoxO1) [40], benfotiamine
could restore both FoxO1 activity and EPCs diﬀerentiation
[40]. Another study showed that chronic incubation of
EPCs isolated from healthy donors with high glucose levels
impaired tube formation capability in vitro (decreasing
eNOS and NO availability) [36], but could be improved by
coincubation with NO [36]. Finally, the same mechanisms
involved in EPC traﬃcking dysfunction are also relevant in
homing and diﬀerentiation process.
3. Preclinical Experience in Reverting Diabetes-
Mediated EPCs Damage
Several successful approaches to revert diabetes-induced
EPCs dysfunction have been described in preclinical models.
Herein, they are listed according to whether they have been
performed in vitro or in animal models.
3.1. In Vitro Studies
Antioxidants. Antioxidants are relevant mediators of EPCs
impairment. Indeed, Ceradini et al. demonstrated that
glyoxavlase 1 overexpression, an antioxidant key factor that
modiﬁes HIF-1α, restored high glucose-induced impairment
of CXCR-4 and eNOS expression in EPCs [41]. Moreover,
glucose-induced impairment of human EPCs was shown to
be reverted by benfotiamine administration which modu-
lates the PI3K/Akt/FoxO1 pathway [40]. Adiponectin-based
conditioning of EPCs isolated from both human peripheral
blood or mouse bone marrow prevented high glucose-
induced senescence that was characterized by decreased ROS
accumulation [33].
Antidiabetic Drugs. Currently used antidiabetic drugs
showed beneﬁcial eﬀects on EPCs number, and function.
Liang et al. cultured EPCs from healthy donors with AGEs
and rosiglitazone [34]. Indeed, rosiglitazone was able to
reduce EPCs apoptosis, to increase cell number and to
enhance migration capacity [34]. Interestingly, insulin was
shown to increase angiogenic potential of EPCs via IGF-1
receptor signal in both healthy donors and T2D patients
[42].
Gene Therapy. S e v e r a la p p r o a c h e sa i m i n gt or e s t o r eE P C s
function by knocking down or overexpressing target genes
were tested in mice models. Di Stefano et al. showed that
EPCs harvested from p66ShcA knockout mice were resistant
to high glucose injury [43]. Diabetic EPCs in which p53
gene was deleted did not exhibit senescence and form regular
vascular-like structures [32]. Finally, ex vivo VEGF gene
transfer in EPCs enhanced EPC proliferation, adhesion, and
incorporation into endothelial cell monolayers [44].
3.2. Animal Studies
Bone Marrow Mobilizing Factors. In 1999 Takahashi et al.
observed that GM-CSF increased circulating EPCs in rabbits
and caused an improvement in hindlimb vascularization
[18]. In a model of hindlimb ischemia-reperfusion, it
was shown that preconditioning with G-CSF and SDF-1α
could partially recover impaired postischemic progenitor
cell mobilization in diabetic rats [22]. Moreover, Gallagher
et al. showed that administration of SDF-1α into wounds4 Experimental Diabetes Research
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Figure 1: Pathways involved in diabetes-induced EPCs toxicity and possible strategies to reverse EPCs damage during bone marrow
mobilization. EPCs recruited from bone marrow are here represented. Hyperglycemia alters CXCR-4/SDF-1α pathway, reduces VEGF levels,
increases eNOS-mediated production of ROS and a reduction in cleaving enzymes activity. ACE inhibitors and GM-CSF administration
improve bone marrow ability to shed EPCs in the periphery. Diabetes-speciﬁc metabolic alterations are in red, linked by red arrows to
the pathways they interfere with. Red vertical arrows, next to intracellular or extracellular molecules, indicate that their concentration is
diminished or increased in diabetic condition compared to nondiabetic status. Drugs with beneﬁcial eﬀect on EPCs are in green, linked by
green arrows to the pathways they interact with. MMP-9: matrix metalloproteinase-9; GLO-1: glyoxalase-1; ROS: reactive oxygen species; NO:
nitric oxide; eNOS: endothelial nitric oxide synthase; HIF1-α: hypoxia inducible factor 1-α;S D F - 1 α: stem cell-derived factor-1α; CXCR-4: C-X-C
chemokine receptor type 4; VEGF: vascular endothelial growth factor; Kit-L: c-Kit ligand.
of diabetic mice reverted EPC altered homing [21]. Our
group recently showed that the targeting of the CXCR4-
SDF-1α axis in diabetic mice induced an increased release
and engraftment of endogenous EPCs leading to neoan-
giogenesis and improved ability to heal diabetic wounds
[45].
Cell Therapy. Tamarat et al. administered bone marrow
mononuclear cells from either non-diabetic or STZ-induced
diabetic mice into a mouse model of hindlimb ischemia,
which in turn was either diabetic or non-diabetic [46].
Administration of diabetic bone-marrow-derived cells to
non-diabetic mice improved neovascularization (compared
to saline infusion) in a less extent than the infusion of
non-diabetic cells, while injection of non-diabetic bone-
marrow-derived cells into diabetic mice improved blood
ﬂow recovery, capillary number, and ischemic/non-ischemic
angiogenic score compared to the infusion of diabetic bone-
marrow-derived cells [46].
Drugs for Cardiomethabolic Control. PPAR-γ agonists were
demonstrated to increase mobilization of bone-marrow-
derived progenitor cells via stimulation of Akt pathway
[47]. ACE or HMG-CoA reductase inhibition resulted in
signiﬁcant increases of EPCs levels [48]. Moreover, ACE
inhibitors proved to increase bone marrow ERK phospho-
rylation and MMP-9 activity, while statin-based therapy
led to enhancement of bone marrow VEGF levels, Akt
phosphorylation, eNOS activity, and normalized ROS levels
[48]. EPCs peripheral levels, during the early postmyocardial
ischemia phase, were increased by ACE inhibitors or statins
treatment in rats, and this eﬀect was also associated with
improved cardiac function and enhanced capillary density in
the peri-ischemic area [48]. Enalapril-treated mice showed aExperimental Diabetes Research 5
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Figure 2: Pathways involved in diabetes-induced EPCs toxicity and possible strategies to reverse EPCs damage during traﬃcking in the
peripheral blood. EPCs traﬃcking in the peripheral blood are here represented. Hyperglycemia, Ox-LDL, and AGEs accumulation induce
an impaired migration ability and reduced cell counts by either increased senescence or increased apoptosis of EPCs in both in vivo and in
vitro assays. Statins, Adiponectin, CoPP, and MAPK inhibitors are able to reverse diabetes-mediated damage on circulating EPCs. Diabetes-
speciﬁc metabolic alterations are in red, linked by red arrows to the pathways they interfere with. Red vertical arrows, next to intracellular or
extracellular molecules, indicate that their concentration is diminished or increased in diabetic condition compared to nondiabetic status.
Drugs with beneﬁcial eﬀect on EPCs are in green, linked by green arrows to the pathways they interact with. ROS: reactive oxygen species;
NO: nitric oxide; eNOS: endothelial nitric oxide synthase; VEGF: vascular endothelial growth factor; Ox-LDL: oxidized low-density lipoprotein;
MAPK: mitogen-activated protein kinase; CoPP: cobalt protoporphyrin; AGEs: advanced glycation end-products; RAGE: receptor for AGE; PKC:
protein kinase C; IL-8: interleukin-8; COX-2: cyclooxygenase-2.
signiﬁcant enhancement in circulating progenitor cell levels
and a sixfold increase in bone marrow contribution to
neoangiogenesis [49]. Interestingly, recent data showed that
insulin resistant rats showed an insulin-signaling defect in
EPCs that reduces EPC survival and that can be reversed by
knocking down NF-kB [50] (see next paragraph).
Gene Therapy. Prevention from diabetes-mediated impair-
ment of in vivo angiogenesis has been shown in p66ShcA
knockout mice [43] .Ar e c e n ts t u d yb yD e s o u z ae ta l .
showed that infusion of EPCs, which were knocked down
for NF-kB, led to a decrease in neointimal hyperplasia
after carotid angioplasty in a model of type 2 diabetes
[51]. Recently, a Phase I clinical trial showed an increase
in neoangiogenesis after intramuscular gene transfer of
plasmidencodinghumanVEGFinpatientswithcriticallimb
ischemia [52].
Restoration of Insulin-Producing Beta Cells Function. We
have recently shown that restoration of normoglycemia by
successful islet transplantation induced increased number
and improved angiogenic ability of EPCs compared to T1D
[13].
4.ClinicalExperienceand Perspectivesin
Reverting Diabetes-MediatedEPCsDamage
4.1. Improvement of Glycometabolic Control. Optimized glu-
cose control is undoubtedly associated with a better outcome
of macro- and microvascular complications in patients
aﬀected by diabetes [53]. We demonstrated that insulin-
independent islet-transplanted patients showed a recovery
of EPCs number and function [13]. Interestingly, diabetes-
mediated EPCs dysfunction has been demonstrated to
be reversed in obese (non-diabetic) subjects after weight
loss [54] meaning that the damage does not seem to be
irreversible.
4.2. ACE Inhibitors. Routinely administered drugs as ACE
inhibitors and angiotensin receptor blockers proved to
beneﬁt EPCs function [55, 56], even though no randomized
clinical trials are available yet, thus suggesting to capitalize6 Experimental Diabetes Research
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on this secondary eﬀect and improve vascular function in
diabetic patients. Bahlmann et al. investigated the eﬀects of
angiotensin II-receptor blockers, olmesartan and irbesartan,
on EPCs in patients with T2D [56]. In both cases, ACE
inhibitorsincreasedperipheralnumberofEPCscomparedto
placebo treatment [56]. In patients with coronary artery dis-
ease, treatment with ACE-inhibitor ramipril was associated
with increase in both peripheral cell count, and functional
activity of EPCs, the latter being assessed by proliferation,
migration, adhesion and formation of vascular structures in
vitro [55].
4.3. Ex Vivo Conditioning. To date, several investigators
explored a strategy to optimize autologous EPCs function by
ex vivo conditioning with growth factors/chemoattractants
(i.e., SDF-1α [21], VEGF [17], IL-8 [13]), antioxidants (i.e.,
benfotiamine [40]), hormones (i.e., adiponectin [29, 33]),
gene therapy (by transfecting EPCs health-relevant genes as
eNOS [20], FoxO1 [36], and HIF-1α [57]), and clinically
available compounds (as p38 MAPK inhibitors [35], CoPP
[58], statins [34, 59], and ACE-inhibitors [48, 49]). All
these studies showed an improvement in EPCs function,
but no application on humans has been tested so far. A
detailed description of all molecular mechanisms involved
in diabetes-mediated EPCs dysfunction and of the reported
compounds potentially able to restore EPCs damage are
described in Figures 1, 2,a n d3.
4.4. Mobilization of EPCs to Overcome EPCs Dysfunction.
Dipeptidyl-peptidase-4 (DPP-4) has been recently shown
to interfere with EPC function. In a recent clinical trial,
Sitagliptin increased the mobilization of EPCs in T2D
patients, possibly mediated by SDF-1α upregulation [60].
Moreover, EPC mobilization is also induced by physical
activity as shown in children exposed to daily exercise
[61]. Other strategies, including the induction of EPCsExperimental Diabetes Research 7
shedding from bone marrow via stem cell mobilizing
factors (i.e., GM-CSF), have been shown to be feasible and
possibly eﬀective, but it may be argued that a nonspeciﬁc
cell mobilization would occur and that autologous EPCs
are anyway dysfunctional. Unfortunately, EPCs have been
demonstrated to be immunogenic [62] and the attractive
proposal of transplanting heterologous EPCs pooled from
healthy donors would necessarily require the employment of
immunosuppressive drugs.
5. Conclusions
Functional EPCs represent a prerequisite for a healthy
cardiovascular system in diabetic patients. Prevention of
diabetes-related macro- and microvascular complications
dramatically inﬂuences the life expectance and the quality
of life of diabetic patients, thus representing a crucial target
for physicians. Already available drugs, currently used in
clinical practice, and novel compounds should be tested
in randomized clinical trials to evaluate their eﬃcacy in
normalizing or reverting diabetes-mediated EPCs damage.
Moreover, ex vivo EPCs expansion, conditioning, and gene
therapy might represent potential future strategies to reverse
EPCs dysfunction, ﬁnally leading to a better cardiovascular
outcome.
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